CG7870

AXP000053.1 · Oncolytic virus

Platform
adenovirus (Ad5, rat probasin promoter-E1A, PSA promoter-E1B, E3 retained)
Originator
Calydon
Sponsor
Cell Genesys

Names

NameTypeSource
CG7870preferred name, codecurator, ctgov
CV787former codepaper

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (CG7870)
Replication
conditionally replicating
Modifications
rat probasin promoter drives E1A; PSA promoter/enhancer drives E1B; full E3 region retained
Route
intratumoral, intravenous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT00103428Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate CancerTerminatedPhase 1/22004-0869Prostate Cancer
NCT00116155Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate CancerCompletedPhase 1/2Prostate Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 16690359A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.Molecular therapy : the journal of the American Society of Gene Therapy2006name in title: CG7870

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 20629483Use of a bioamplification assay to detect nonselective recombinants and assess the genetic stability of oncolytic adenoviruses.Human gene therapy2010name in abstract: CG7870
PMID 15832172Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.Cancer gene therapy2005name in title: CG7870
PMID 12435044Selectively replicating oncolytic adenoviruses as cancer therapeutics.Current opinion in molecular therapeutics2002name in abstract: CG7870
PMID 12522437Intravascular adenoviral agents in cancer patients: lessons from clinical trials.Cancer gene therapy2002name in abstract: CG7870
PMID 11212244Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.Cancer research2001name in title: CV787
PMID 11338935Technology evaluation: CV-787, Calydon Inc.Current opinion in molecular therapeutics2001name in title: CV787
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 10485454The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.Cancer research1999name in abstract: CV787

Notes

Formerly CV787. Intraprostatic phase I and intravenous phase I/II (NCT00103428 with docetaxel, NCT00116155) in hormone-refractory prostate cancer. Discontinued; Cell Genesys merged into BioSante in 2009.

How to cite

CG7870 (AXP000053.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000053.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.